← Back to Screener
Lexeo Therapeutics, Inc. Common Stock (LXEO)
Price$6.58
Favorite Metrics
Price vs S&P 500 (26W)-19.30%
Price vs S&P 500 (4W)12.34%
Market Capitalization$503.79M
All Metrics
Book Value / Share (Quarterly)$3.38
P/TBV (Annual)3.95x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.36
Price vs S&P 500 (YTD)-34.16%
Net Profit Margin (TTM)-11991.84%
EPS (TTM)$-2.19
10-Day Avg Trading Volume1.28M
EPS Excl Extra (TTM)$-2.19
EPS (Annual)$-3.06
ROI (Annual)-82.89%
Cash / Share (Quarterly)$2.49
ROA (Last FY)-66.69%
EBITD / Share (TTM)$-2.03
ROE (5Y Avg)-56.75%
Operating Margin (TTM)-12408.36%
Cash Flow / Share (Annual)$-1.36
P/B Ratio2.04x
P/B Ratio (Quarterly)2.94x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-33.33x
ROA (TTM)-55.98%
EPS Incl Extra (Annual)$-3.06
Current Ratio (Annual)11.21x
Quick Ratio (Quarterly)10.81x
3-Month Avg Trading Volume1.13M
52-Week Price Return217.76%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.68
P/S Ratio (Annual)775.06x
Asset Turnover (Annual)0.01x
52-Week High$10.99
EPS Excl Extra (Annual)$-3.06
26-Week Price Return-15.32%
Quick Ratio (Annual)10.81x
13-Week Price Return-16.26%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.21x
Enterprise Value$441.637
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-9120.00%
Cash / Share (Annual)$2.49
3-Month Return Std Dev75.53%
Net Income / Employee (TTM)$-1
ROE (Last FY)-83.87%
EPS Basic Excl Extra (Annual)$-3.06
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.19
ROI (TTM)-66.86%
P/S Ratio (TTM)535.16x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.92
Price vs S&P 500 (52W)187.93%
Year-to-Date Return-31.52%
5-Day Price Return5.75%
EPS Normalized (Annual)$-3.06
ROA (5Y Avg)-45.95%
Net Profit Margin (Annual)-9120.00%
Month-to-Date Return18.47%
Cash Flow / Share (TTM)$-2.56
EBITD / Share (Annual)$-3.04
Operating Margin (Annual)-9309.23%
LT Debt / Equity (Annual)2.29x
ROI (5Y Avg)-55.88%
LT Debt / Equity (Quarterly)3.51x
EPS Basic Excl Extra (TTM)$-2.19
P/TBV (Quarterly)6.87x
P/B Ratio (Annual)2.94x
Pretax Margin (TTM)-11991.84%
Book Value / Share (Annual)$3.38
Price vs S&P 500 (13W)-16.94%
Beta2.62x
Revenue / Share (TTM)$0.00
ROE (TTM)-67.33%
52-Week Low$1.97
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.41
4.41
4.41
4.41
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LXEOLexeo Therapeutics, Inc. Common Stock | 535.16x | — | — | — | $6.58 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Lexeo Therapeutics is a clinical-stage biopharmaceutical company focused exclusively on developing gene therapies for hereditary and acquired genetic diseases with high unmet medical needs. The company applies genetic medicine approaches to address conditions with limited existing treatment options.